Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
GSK's ViiV Healthcare Says HIV Treatment Cabenuva's Latest Trial Meets Primary Endpoint

GSK's ViiV Healthcare Says HIV Treatment Cabenuva's Latest Trial Meets Primary Endpoint

MT newswireMT newswire2026/10/06 13:42

09:42 AM EDT, 10/06/2026 (MT Newswires) -- ViiV Healthcare, which is majority owned by GSK (GSK), said Tuesday that a phase 3b study has met its primary endpoint, showing that at six months, Cabenuva saw "superior rates of viral suppression" compared with oral antiretroviral therapy in adults and adolescents with HIV-1, who had detectable virus when they started the trial. The trial has enrolled 326 participants in eight countries at 85 study sites, the company said. The results follow a previous trial that showed that Cabenuva was superior to daily oral therapy in keeping viral suppression for people with HIV who had reached viral suppression on oral antiretroviral therapy but had a history of adherence challenges, ViiV said. The latest trial addressed a "remaining evidence gap by evaluating direct initiation of the regimen in people who still had detectable virus at study entry," the company said. ViiV said the latest results will now be shared with health regulators. Price: 46.77, Change: +0.24, Percent Change: +0.52

09:42 AM EDT, 10/06/2026 (MT Newswires) -- ViiV Healthcare, which is majority owned by GSK (GSK), said Tuesday that a phase 3b study has met its primary endpoint, showing that at six months, Cabenuva saw "superior rates of viral suppression" compared with oral antiretroviral therapy in adults and adolescents with HIV-1, who had detectable virus when they started the trial. The trial has enrolled 326 participants in eight countries at 85 study sites, the company said. The results follow a previous trial that showed that Cabenuva was superior to daily oral therapy in keeping viral suppression for people with HIV who had reached viral suppression on oral antiretroviral therapy but had a history of adherence challenges, ViiV said. The latest trial addressed a "remaining evidence gap by evaluating direct initiation of the regimen in people who still had detectable virus at study entry," the company said. ViiV said the latest results will now be shared with health regulators. Price: 46.77, Change: +0.24, Percent Change: +0.52
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

BUZZ-SpaceX seeks 40 billions USD in financing to purchase Nvidia chips, stock price drops in response

October 7 - SpaceX (SPCX.O) shares fell 1.8% in premarket trading to $168.9. According to the Financial Times, citing people familiar with the matter, the company plans to raise $40 billions to acquire Nvidia (NVDA.O) AI chips. The Financial Times reports that the proposed financing, led by Apollo Global Management (APO.N), includes around $10 billions in bank loans and $30 billions in investment-grade bonds to pay for the chip orders. This move by Elon Musk's company underscores the enormous capital required amid the AI boom, as tech companies race to expand their computing infrastructure. SpaceX, Apollo Global Management, and Nvidia have yet to respond to Reuters' requests for comment. Out of 41 brokerages, 32 have a "Buy" or higher rating on the stock, 6 rate it "Hold," and 3 as "Sell" or lower; the median target price is $217, according to data compiled by London Stock Exchange Group (LSEG). As of the previous trading session close, SPCX shares have risen 27.3% from their IPO price of $135.

路透社•2026/10/07 08:51

BUZZ - Constellation Brands shares fall after lowering profit margin expectations

October 7 - Constellation Brands (STZ.N) shares fell nearly 5% in pre-market trading to $110.11. The Corona beer maker lowered its full-year operating margin forecast to 31%-32% from the previous 32%-33%. The company reported Q2 profit and sales on Tuesday that exceeded expectations, driven by strong demand for beers such as Modelo Especial and Victoria, which helped offset challenges in the alcohol sector amid weak consumption. JPMorgan stated that Q2 FY2027 financial results were largely in line with expectations; market focus may turn to management's outlook for H2 FY2027 beer business revenue and operating margins, and the implications for FY2028. The company will pay $75 million to acquire the vodka-based ready-to-drink (RTD) brand SpikedAde upon transaction completion, with up to a further $278 million over five years depending on brand performance and capital allocation priorities. “Although the brand and category are still nascent, the acquisition of SpikedAde could hold significant potential,” said JPMorgan. As of yesterday's close, the stock is down 16% year to date.

路透社•2026/10/07 08:51

Advanced Micro Devices CEO Reportedly Seeks Samsung Partnership, Meets Korean Executives

04:37 AM EDT, 10/07/2026 (MT Newswires) -- Advanced Micro Devices (AMD) is pursuing a collaboration with Samsung Electronics in memory and chip manufacturing, multiple outlets reported Wednesday, citing Chief Executive Lisa Su and an unnamed person familiar with the matter. Su reportedly held talks with SK Hynix (SKHY) leadership and scheduled a meeting with Samsung semiconductor head Jun Young-hyun during a trip to South Korea, the reports said. The company depends heavily on South Korean suppliers to reach its data center targets and is encouraging manufacturers to improve output, Reuters quoted Su as saying. AMD, Samsung Electronics, and SK Hynix did not immediately respond to MT Newswires' request for comment.

MT newswire•2026/10/07 08:37